ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.

ABSTRACT:

Background

Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels of current neuroendocrine markers exhibit high case-by-case variability, so multiple markers are used in combination to identify SCNCs. Here, we report that ACAA2 is elevated in SCNCs and is a potential molecular indicator for SCNCs.

Methods

ACAA2 expressions in tumour xenografts, tissue microarrays (TMAs), and patient tissues from prostate and lung cancers were analysed via immunohistochemistry. ACAA2 mRNA levels in lung and prostate cancer (PC) patients were assessed in published datasets.

Results

ACAA2 protein and mRNA lev

SUBMITTER: Shen M 

PROVIDER: S-EPMC10667239 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature